Répertoire du corps professoral
Guy Boivin
Médecin clinicien enseignant titulaire
guy.boivin@fmed.ulaval.ca
Pavillon Ferdinand-Vandry
1050, avenue de la Médecine
Mise au point d'un modèle animal pour l'infection avec le virus parainfluenza-3
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 10 janvier 2024
au10 janvier 2026
Identification of innate immune pathways as targets for immunomodulatory therapy in herpes simplex virus encephalitis
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2023
au30 septembre 2028
Plateforme de laboratoire de niveau de confinement 3 pour la recherche sur les virus émergents
Programme: Appel de projets en appui aux plateformes technologiques stratégiques
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL, Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université Laval
Du 31 janvier 2023
au31 mars 2025
Évaluation des interactions entre des virus respiratoires
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 février 2022
au31 janvier 2025
CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal
Programme: Subvention de fonctionnement:Nouveaux besoins prioritaires en recherche sur la COVID-19
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université de Montréal
Du 1 décembre 2021
au31 mars 2025
Laboratoire international associé (LIA) sur la pathogenèse, le traitement et la prévention des infections virales respiratoires (LIA RespiVIR)
Programme: Laboratoire international associé (LIA)
Organisme(s) subventionnaire(s): Université Laval - Fonds internes
Type de financement: Subvention
Établissement tête: Université Laval
Du 27 juillet 2021
au26 juillet 2026
Financements des 2 dernières années
Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mars 2023
au29 février 2024
Relationship between COVID-19 and Parkinson’s disease in a mouse model
Programme: Programme de projets pilotes
Organisme(s) subventionnaire(s): Parkinson Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2022
au31 mars 2024
SO06 QC07 Sentinel Surveillance for Severe Outcomes of Laboratory-Confirmed Influenza in Adults for the Annual Influenza Season and for Confirmed and Suspected Cases Of Covid-19/Sars-Cov-2 Acute Respiratory Disease, Covid-19[...]
Programme: Réseau canadien de recherche sur l’immunisation
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Dalhousie University
Du 1 avril 2022
au31 mars 2023
COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal
Programme: Subvention de fonctionnement:Nouveaux besoins prioritaires en recherche sur la COVID-19
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2021
au30 novembre 2022
Manufacturing of antigens and adjuvants for development of vaccines (MAAV)
Programme: Fonds d'innovation (FI)
Organisme(s) subventionnaire(s): Fondation Canadienne pour l'innovation (La), Ministère de la Santé et des Services sociaux, Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2021
au31 mars 2024
Changement de paradigme dans la conduite d'essais cliniques
Organisme(s) subventionnaire(s): Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université de Montréal
Du 1 avril 2021
au31 mars 2024
SO05 QC07, Sentinel surveillance for confirmed and suspected cases of covid-19/covsars-2 acute respiratory disease, covid-19 vaccine effectiveness and adverse events following sars-cv-2 vaccines: A study of the Serious Outcomes Surveillance
Programme: Réseau canadien de recherche sur l’immunisation
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2021
au30 septembre 2023
Innovative therapeutic approaches for the 2019-novel coronavirus
Programme: Subvention de fonctionnement : Possibilité de financement canadienne pour une intervention de recherche rapide contre la maladie à coronavirus 2019 (COVID-19)
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada, Secrétariat Inter-Conseils (Canada) (CRSH, CRSNG, IRSC)
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mars 2021
au31 mars 2024
Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE)
Organisme(s) subventionnaire(s): Agence de la santé publique du Canada
Type de financement: Subvention
Établissement tête: Dalhousie University
Du 1 novembre 2020
au30 septembre 2022
How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens
Organisme(s) subventionnaire(s): Ministère de l'Économie, de la Science et de l'Innovation, GenePOC inc., CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2018
au30 septembre 2022
A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses
Programme: Subventions Fondation
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2016
au30 juin 2023
Encadrements terminés dans les 5 dernières années
Publications des 5 dernières années
The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study JMIR Public Health and Surveillance, 2024/05/06. Rodica Gilca, Rachid Amini, Sara Carazo, Radhouene Doggui, Charles Frenette, Guy Boivin, Hugues Charest, Jeannot Dumaresq. DOI 10.2196/40792
Viral interference between severe acute respiratory syndrome coronavirus 2 and influenza A viruses 2024/02/03. Shella Gilbert-Girard, Jocelyne Piret, Julie Carbonneau, Mathilde Hénaut, Nathalie Goyette, Guy Boivin. DOI 10.1101/2024.02.02.578538
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir Infectious Disease Reports, 2024/01/18. Jocelyne Piret, Guy Boivin. DOI 10.3390/idr16010005
The impact of trained immunity in respiratory viral infections Reviews in Medical Virology, 2024/01. Jocelyne Piret, Guy Boivin. DOI 10.1002/rmv.2510
Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs Microorganisms, 2023/04/22. Amel Saim-Mamoun, Julie Carbonneau, Chantal Rhéaume, Yacine Abed, Guy Boivin. DOI 10.3390/microorganisms11051095
Duration of isolation and contagiousness in coronavirus disease 2019 (COVID-19) patients receiving tocilizumab and dexamethasone: A case series Infection Control & Hospital Epidemiology, 2023/04. Florence Côté, Guy Boivin, Vilayvong Loungnarath, Annie Ruest, Julie Bestman-Smith, Julie Carbonneau, Marie-Ève Hamelin, Marie-Claude Roy. DOI 10.1017/ice.2022.14
A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice Biomedicines, 2022/10/08. Hugues Fausther-Bovendo, Marie-Eve Hamelin, Julie Carbonneau, Marie-Christine Venable, Liva Checkmahomed, Pierre-Olivier Lavoie, Marie-Ève Ouellet, Guy Boivin, Marc-André D’Aoust, Gary P. Kobinger. DOI 10.3390/biomedicines10102516
Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid Pathogens, 2022/09/15. Amel Saim-Mamoun, Yacine Abed, Julie Carbonneau, Guy Boivin. DOI 10.3390/pathogens11091048
The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers Influenza and Other Respiratory Viruses, 2022/09. Étienne Racine, Guy Boivin, Yves Longtin, Deirdre McCormack, Hélène Decaluwe, Patrice Savard, Matthew P. Cheng, Marie‐Ève Hamelin, Julie Carbonneau, Fazia Tadount, Kelsey Adams, Benoîte Bourdin, Sabryna Nantel, Vladimir Gilca, Jacques Corbeil, Gaston De Serres, Caroline Quach‐Thanh. DOI 10.1111/irv.12997
Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 2022/09/01. Florence Côté, Julie Bestman-Smith, Marie Gourdeau, Shawn M Simpson, Marie-Ève Hamelin, Julie Carbonneau, Antoine Chiasson, Marieke Rozendaal, Martin A Smith, Guy Boivin. DOI 10.3138/jammi-2021-0036
The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study (Preprint) 2022/07/05. Rodica Gilca, Rachid Amini, Sara Carazo, Radhouene Doggui, Charles Frenette, Guy Boivin, Hugues Charest, Jeannot Dumaresq. DOI 10.2196/preprints.40792
The changing landscape of respiratory viruses contributing to respiratory hospitalisations: results from a hospital-based surveillance in Quebec, Canada, 2012-13 to 2021-22 2022/07/02. Rodica Gilca, Rachid Amini, Sara Carazo, Charles Frenette, Guy Boivin, Hugues Charest, Jeannot Dumaresq. DOI 10.1101/2022.07.01.22277061
In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes Antiviral Research, 2022/06. Jocelyne Piret, Nathalie Goyette, Guy Boivin. DOI 10.1016/j.antiviral.2022.105328
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19 International Journal of Infectious Diseases, 2022/03. Jean-Claude Tardif, Mariève Cossette, Marie-Claude Guertin, Nadia Bouabdallaoui, Marie-Pierre Dubé, Guy Boivin. DOI 10.1016/j.ijid.2022.01.020
Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells Viruses, 2022/02/15. Clément Fage, Mathilde Hénaut, Julie Carbonneau, Jocelyne Piret, Guy Boivin. DOI 10.3390/v14020395
In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance 2022/02/12. Liva Checkmahomed, Venice Du Pont, Nicholas C. Riola, Jason K. Perry, Jiani Li, Danielle P. Porter, Guy Boivin. DOI 10.1101/2022.02.07.479493
The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers 2022/02/10. Étienne Racine, Guy Boivin, Yves Longtin, Deirde McCormack, Hélène Decaluwe, Patrice Savard, Matthew P. Cheng, Marie-Ève Hamelin, Fazia Tadount, Kelsey Adams, Benoîte Bourdin, Sabryna Nantel, Vladimir Gilca, Jacques Corbeil, Gaston De Serres, Caroline Quach. DOI 10.1101/2022.02.10.22269967
Viral Interference between Respiratory Viruses. Emerging infectious diseases, 2022/02. Piret J, Boivin G. DOI 10.3201/eid2802.211727
Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice Journal of Neuroinflammation, 2021/12. William Enlow, Maude Bordeleau, Jocelyne Piret, Fernando González Ibáñez, Olus Uyar, Marie-Christine Venable, Nathalie Goyette, Julie Carbonneau, Marie-Eve Tremblay, Guy Boivin. DOI 10.1186/s12974-021-02221-z
Antiviral Drugs Against Herpesviruses Antiviral Drug Discovery and Development, 2021/07. Jocelyne Piret, Guy Boivin. DOI 10.1007/978-981-16-0267-2_1
Older Age and Frailty Are Associated With Higher Mortality but Lower Intensive Care Unit Admission Among Adults Admitted to Canadian Hospitals With COVID-19: A Report From the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance Network 2021/05. Andrew M, Godin J, LeBlanc J, Boivin G, Valiquette L, McElhaney JE, Hatchette TF, ElSherif M, MacKinnon-Cameron D, Ambrose A, Trottier S, Loeb M, McNeil S. DOI 10.2139/ssrn.3844895
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. The Lancet. Respiratory medicine, 2021/05. Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, COLCORONA Investigators. DOI 10.1016/s2213-2600(21)00222-8
Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: Protocol for a cohort study in Montreal, Canada 2021/04. Zinszer K, McKinnon B, Bourque N, Zahreddine M, Charland K, Papenburg J, Fortin G, Hamelin M, Saucier A, Apostolatos A, Pierce L, Savard-Lamothe A, Quach C. DOI 10.1101/2021.04.14.21255499
Impact of Amino Acid Substitutions in Region II and Helix K of HSV-1 and HCMV DNA Polymerases on Resistance to Foscarnet. Antimicrobial agents and chemotherapy, 2021/04. Zarrouk K, Zhu X, Pham VD, Goyette N, Piret J, Shi R, Boivin G. DOI 10.1128/aac.00390-21
Zika virus and impact on male fertility Zika Virus Biology, Transmission, and Pathology, 2021. Jocelyne Piret, Guy Boivin. DOI 10.1016/b978-0-12-820268-5.00026-2
RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions Viruses, 2021. Geiser, J., Boivin, G., Huang, S., Constant, S., Kaiser, L., Tapparel, C., Essaidi-Laziosi, M.. DOI 10.3390/v13010139
Pandemics Throughout History Frontiers in Microbiology, 2021. Piret, J., Boivin, G.. DOI 10.3389/fmicb.2020.631736
Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples Journal of Infectious Diseases, 2021. Nicolas De Lamballerie, C., Pizzorno, A., Dubois, J., Padey, B., Julien, T., Traversier, A., Carbonneau, J., Orcel, E., Lina, B., Hamelin, M.-E., Roche, M., Textoris, J., Boivin, G., Legras-Lachuer, C., Terrier, O., Rosa-Calatrava, M.. DOI 10.1093/infdis/jiaa468
Genetics of symptom remission in outpatients with COVID-19 Scientific Reports, 2021. Dubé, M.-P., Lemaçon, A., Barhdadi, A., Lemieux Perreault, L.-P., Oussaïd, E., Asselin, G., Provost, S., Sun, M., Sandoval, J., Legault, M.-A., Mongrain, I., Dubois, A., Valois, D., Dedelis, E., Lousky, J., Choi, J., Goulet, E., Savard, C., Chicoine, L.-M., Cossette, M., Chabot-Blanchet, M., Guertin, M.-C., de Denus, S., Bouabdallaoui, N., Marchand, R., Bassevitch, Z., Nozza, A., Gaudet, D., L’Allier, P.L., Hussin, J., Boivin, G., Busseuil, D., Tardif, J.-C.. DOI 10.1038/s41598-021-90365-6
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review Reviews in Medical Virology, 2021. Abed, Y., Saim-Mamoun, A., Boivin, G.. DOI 10.1002/rmv.2175
Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases Antiviral Research, 2021. Zarrouk, K., Zhu, X., Goyette, N., Piret, J., Shi, R., Boivin, G.. DOI 10.1016/j.antiviral.2021.105046
DNA polymerases of herpesviruses and their inhibitors Viral Replication Enzymes and their Inhibitors Part B, 2021. Jocelyne Piret, Guy Boivin. DOI 10.1016/bs.enz.2021.07.003
Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 2021/01. Tardif J, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, for the COLCORONA Investigators. DOI 10.1101/2021.01.26.21250494
Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults Journal of Medical Microbiology, 2020. LeBlanc, J.J., ElSherif, M., Mulpuru, S., Warhuus, M., Ambrose, A., Andrew, M., Boivin, G., Bowie, W., Chit, A., Dos Santos, G., Green, K., Halperin, S.A., Hatchette, T.F., Ibarguchi, B., Johnstone, J., Katz, K., Langley, J.M., Lagacé-Wiens, P., Loeb, M., Lund, A., MacKinnon-Cameron, D., McCarthy, A., McElhaney, J.E., McGeer, A., Poirier, A., Powis, J., Richardson, D., Semret, M., Shinde, V., Smyth, D., Trottier, S., Valiquette, L., Webster, D., Ye, L., McNeil, S.A.. DOI 10.1099/jmm.0.001032
Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection Vaccine, 2020. Mandon, E.D., Pizzorno, A., Traversier, A., Champagne, A., Hamelin, M.E., Lina, B., Boivin, G., Dejean, E., Rosa-Calatrava, M., Jawhari, A.. DOI 10.1016/j.vaccine.2019.10.018
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient Antiviral Therapy, 2020. Abed, Y., Schibler, M., Checkmahomed, L., Carbonneau, J., Venable, M.-C., Fage, C., Giannotti, F., Goncalves, A.R., Kaiser, L., Boivin, G.. DOI 10.3851/imp3344
Modified cyclodextrins as broad-spectrum antivirals Science Advances, 2020. Jones, S.T., Cagno, V., Janeček, M., Ortiz, D., Gasilova, N., Piret, J., Gasbarri, M., Constant, D.A., Han, Y., Vuković, L., Král, P., Kaiser, L., Huang, S., Constant, S., Kirkegaard, K., Boivin, G., Stellacci, F., Tapparel, C.. DOI 10.1126/sciadv.aax9318
Infectivity of healthcare workers diagnosed with SARS-CoV-2 infection approximately 2 weeks after onset of symptoms: A cross-sectional study Infection Control and Hospital Epidemiology, 2020. Longtin, Y., Charest, H., Quach, C., Savard, P., Baz, M., Boivin, G., Farfard, J., Villeneuve, J., Roger, M., de Serres, G.. DOI 10.1017/ice.2020.1420
In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza a viruses Viruses, 2020. Checkmahomed, L., Padey, B., Pizzorno, A., Terrier, O., Rosa-Calatrava, M., Abed, Y., Baz, M., Boivin, G.. DOI 10.3390/v12101139
Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains The Journal of infectious diseases, 2020. Checkmahomed, L., M'hamdi, Z., Carbonneau, J., Venable, M.-C., Baz, M., Abed, Y., Boivin, G.. DOI 10.1093/infdis/jiz418
Immunomodulatory strategies in herpes simplex virus encephalitis Clinical Microbiology Reviews, 2020. Piret, J., Boivin, G.. DOI 10.1128/CMR.00105-19
Hypersusceptibility of human cytomegalovirus to foscarnet induced by mutations in helices K and P of the viral DNA polymerase Antimicrobial Agents and Chemotherapy, 2020. Zarrouk, K., Pham, V.D., Piret, J., Shi, R., Boivin, G.. DOI 10.1128/AAC.01910-19
Frailty hinders recovery from influenza and acute respiratory illness in older adults Journal of Infectious Diseases, 2020. Lees, C., Godin, J., McElhaney, J.E., McNeil, S.A., Loeb, M., Hatchette, T.F., LeBlanc, J., Bowie, W., Boivin, G., McGeer, A., Poirier, A., Powis, J., Semret, M., Webster, D., Andrew, M.K.. DOI 10.1093/infdis/jiaa092
Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice Vaccine, 2020. Pilaev, M., Shen, Y., Carbonneau, J., Venable, M.-C., Rhéaume, C., Lavigne, S., Couture, C., Guarné, A., Hamelin, M.-È., Boivin, G.. DOI 10.1016/j.vaccine.2020.01.047
Engineering of live chimeric vaccines against human metapneumovirus Pathogens, 2020. Makowska, D.O., Hamelin, M.-È., Boivin, G.. DOI 10.3390/pathogens9020135
Effects of different drug combinations in immunodeficient mice infected with an influenza a/h3n2 virus Microorganisms, 2020. Mhamdi, Z., Fausther-Bovendo, H., Uyar, O., Carbonneau, J., Venable, M.-C., Abed, Y., Kobinger, G., Boivin, G., Baz, M.. DOI 10.3390/microorganisms8121968
Droplet Digital PCR and Immunohistochemistry Techniques to Detect Zika Virus in the Central Nervous System of Mice Methods in Molecular Biology, 2020. Enlow, W., Piret, J., Boivin, G.. DOI 10.1007/978-1-0716-0581-3_4
Cytomegalovirus seropositivity is associated with increased microbial translocation in people living with human immunodeficiency virus and uninfected controls Clinical Infectious Diseases, 2020. Ramendra, R., Isnard, S., Lin, J., Fombuena, B., Ouyang, J., Mehraj, V., Zhang, Y., Finkelman, M., Costiniuk, C., Lebouché, B., Chartrand-Lefebvre, C., Durand, M., Tremblay, C., Ancuta, P., Boivin, G., Routy, J.-P.. DOI 10.1093/cid/ciz1001
Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice Antiviral Research, 2020. Abed, Y., Fage, C., Checkmahomed, L., Venable, M.-C., Boivin, G.. DOI 10.1016/j.antiviral.2020.104807
An Early Microglial Response Is Needed to Efficiently Control Herpes Simplex Virus Encephalitis Journal of Virology, 2020. Uyar, O., Laflamme, N., Piret, J., Venable, M.-C., Carbonneau, J., Zarrouk, K., Rivest, S., Boivin, G.. DOI 10.1128/JVI.01428-20
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015 BMJ Open Respiratory Research, 2020. Leblanc, J., Elsherif, M., Ye, L., Mackinnon-Cameron, D., Ambrose, A., Hatchette, T.F., Lang, A.L.S., Gillis, H.D., Martin, I., Demczuk, W.H., Laferriere, C., Andrew, M.K., Boivin, G., Bowie, W., Green, K., Johnstone, J., Loeb, M., McCarthy, A., McGeer, A., Semret, M., Trottier, S., Valiquette, L., Webster, D., McNeil, S.A.. DOI 10.1136/bmjresp-2019-000550
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization Journal of Infectious Diseases, 2019. De La Vega, M.-A., Piret, J., Griffin, B.D., Rhéaume, C., Venable, M.-C., Carbonneau, J., Couture, C., Das Neves Almeida, R., Tremblay, R.R., Magalhães, K.G., Park, Y.K., Roberts, C.C., Maslow, J.N., Sardesai, N.Y., Kim, J.J., Muthumani, K., Weiner, D.B., Kobinger, G.P., Boivin, G.. DOI 10.1093/infdis/jiy336
The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis Journal of NeuroVirology, 2019. Canivet, C., Uyar, O., Rhéaume, C., Piret, J., Boivin, G.. DOI 10.1007/s13365-019-00730-5
The nonstructural NS1 protein of influenza viruses modulates TP53 splicing through host factor CPSF4 Journal of Virology, 2019. Dubois, J., Traversier, A., Julien, T., Padey, B., Lina, B., Bourdon, J.-C., Marcel, V., Boivin, G., Rosa-Calatrava, M., Terrier, O.. DOI 10.1128/JVI.02168-18
The impact of prior season vaccination on subsequent influenza vaccine effectiveness to prevent influenza-related hospitalizations over 4 influenza seasons in Canada Clinical Infectious Diseases, 2019. Nichols, M.K., Andrew, M.K., Ye, L., Hatchette, T.F., Ambrose, A., Boivin, G., Bowie, W., Dos Santos, G., Elsherif, M., Green, K., Haguinet, F., Katz, K., Leblanc, J., Loeb, M., Mackinnon-Cameron, D., McCarthy, A., McElhaney, J.E., McGeer, A., Powis, J., Richardson, D., Semret, M., Sharma, R., Shinde, V., Smyth, D., Trottier, S., Valiquette, L., Webster, D., McNeil, S.A.. DOI 10.1093/cid/ciy1009
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors Antiviral Research, 2019. Abed, Y., Fage, C., Checkmahomed, L., Begin, G., Carbonneau, J., Lague, P., Boivin, G.. DOI 10.1016/j.antiviral.2019.104561
Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus Scientific Reports, 2019. Baz, M., M’hamdi, Z., Carbonneau, J., Lavigne, S., Couture, C., Abed, Y., Boivin, G.. DOI 10.1038/s41598-019-51877-4
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN) Vaccine, 2019. LeBlanc, J.J., ElSherif, M., Ye, L., MacKinnon-Cameron, D., Ambrose, A., Hatchette, T.F., Lang, A.L.S., Gillis, H.D., Martin, I., Demczuk, W., Andrew, M.K., Boivin, G., Bowie, W., Green, K., Johnstone, J., Loeb, M., McCarthy, A.E., McGeer, A., Semret, M., Trottier, S., Valiquette, L., Webster, D., McNeil, S.A.. DOI 10.1016/j.vaccine.2019.05.003
Strain-dependent impact of G and SH deletions provide new insights for live-attenuated HMPV vaccine development Vaccines, 2019. Dubois, J., Pizzorno, A., Cavanagh, M.-H., Padey, B., De Lamballerie, C.N., Uyar, O., Venable, M.-C., Carbonneau, J., Traversier, A., Julien, T., Lavigne, S., Couture, C., Lina, B., Hamelin, M.-È., Terrier, O., Rosa-Calatrava, M., Boivin, G.. DOI 10.3390/vaccines7040164
Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures Frontiers in Immunology, 2019. Pizzorno, A., Terrier, O., de Lamballerie, C.N., Julien, T., Padey, B., Traversier, A., Roche, M., Hamelin, M.-E., Rhéaume, C., Croze, S., Escuret, V., Poissy, J., Lina, B., Legras-Lachuer, C., Textoris, J., Boivin, G., Rosa-Calatrava, M.. DOI 10.3389/fimmu.2019.00060
Reduced susceptibility to neuraminidase inhibitors in influenza b isolate, Canada Emerging Infectious Diseases, 2019. Abed, Y., Fage, C., Lagüe, P., Carbonneau, J., Papenburg, J., Vinh, D.C., Boivin, G.. DOI 10.3201/EID2504.181554
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes npj Vaccines, 2019. Del Campo, J., Pizzorno, A., Djebali, S., Bouley, J., Haller, M., Pérez-Vargas, J., Lina, B., Boivin, G., Hamelin, M.-E., Nicolas, F., Le Vert, A., Leverrier, Y., Rosa-Calatrava, M., Marvel, J., Hill, F.. DOI 10.1038/s41541-019-0098-4
Novel antiviral compounds and combination therapy for influenza viruses,Nouveaux composés antiviraux et thérapie combinée contre les virus influenza Virologie, 2019. Boivin, G., Rosa-Calatrava, M., Lina, B.. DOI 10.1684/vir.2019.0802
Novel antiviral compounds and combination therapy for influenza viruses,Nouveaux composés antiviraux et thérapie combinée contre les virus influenza Virologie, 2019. Boivin, G., Rosa-Calatrava, M., Lina, B.. DOI 10.1684/vir.2019.0803
Molecular and epidemiologic investigation of a rhinovirus outbreak in a neonatal intensive care unit Infection Control and Hospital Epidemiology, 2019. El Idrissi, K.R., Isabel, S., Carbonneau, J., Lafond, M., Quach, C., Caya, C., Fontela, P.S., Beltempo, M., Boivin, G., Lefebvre, M.-A., Papenburg, J.. DOI 10.1017/ice.2018.311
Influenza virus epidemiology: A permanent vaccine challenge,Épidémiologie des virus influenza: Le défi vaccinal permanent Virologie, 2019. Boivin, G., Lina, B.. DOI 10.1684/vir.2019.0788
In vitro properties and virulence of contemporary recombinant influenza b viruses harboring mutations of cross-resistance to neuraminidase inhibitors Viruses, 2019. Fage, C., Abed, Y., Checkmahomed, L., Venable, M.-C., Boivin, G.. DOI 10.3390/v11010006
Human parainfluenza 2 related illness and a death in a group of captive western lowland gorillas (gorilla gorilla gorilla) Journal of Zoo and Wildlife Medicine, 2019. Couture, É.L., Ferrell, S.T., Desmarchelier, M., Hamelin, M.-E., Sánchez Mendoza, L.J., Carbonneau, J., Abrahamyan, L., Boivin, G., Lair, S.. DOI 10.1638/2018-0237
Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its smallhydrophobic protein which plays adetrimental role during infection in mice PLoS Pathogens, 2019. Le, V.B., Dubois, J., Couture, C., Cavanagh, M.H., Uyar, O., Pizzorno, A., Rosa-Calatrava, M., Hamelin, M.E., Boivin, G.. DOI 10.1371/journal.ppat.1007689
Herpes simplex encephalitis in adult patients with MASP-2 deficiency PLoS Pathogens, 2019. Bibert, S., Piret, J., Quinodoz, M., Collinet, E., Zoete, V., Michielin, O., Menasria, R., Meylan, P., Bihl, T., Erard, V., Fellmann, F., Rivolta, C., Boivin, G., Bochud, P.-Y.. DOI 10.1371/journal.ppat.1008168
Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD Chest, 2019. Mulpuru, S., Li, L., Ye, L., Hatchette, T., Andrew, M.K., Ambrose, A., Boivin, G., Bowie, W., Chit, A., Dos Santos, G., ElSherif, M., Green, K., Haguinet, F., Halperin, S.A., Ibarguchi, B., Johnstone, J., Katz, K., Langley, J.M., LeBlanc, J., Loeb, M., MacKinnon-Cameron, D., McCarthy, A., McElhaney, J.E., McGeer, A., Powis, J., Richardson, D., Semret, M., Shinde, V., Smyth, D., Trottier, S., Valiquette, L., Webster, D., McNeil, S.A., Lagace-Wiens, P., Light, B., Poirier, A., Smith, S., Taylor, G.. DOI 10.1016/j.chest.2018.10.044
Design and validation with influenza a virus of an aerosol transmission chamber for ferrets International Journal of Environmental Research and Public Health, 2019. Turgeon, N., Hamelin, M.-È., Verreault, D., Lévesque, A., Rhéaume, C., Carbonneau, J., Checkmahomed, L., Girard, M., Boivin, G., Duchaine, C.. DOI 10.3390/ijerph16040609
Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis Journal of Infectious Diseases, 2019. Piret, J., Schibler, M., Pham, V.D., Hantz, S., Giannotti, F., Masouridi-Levrat, S., Kaiser, L., Goyette, N., Alain, S., Shi, R., Boivin, G.. DOI 10.1093/infdis/jiz298
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance Antiviral Research, 2019. Piret, J., Boivin, G.. DOI 10.1016/j.antiviral.2019.01.011
Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia Scientific Reports, 2019. Nicolas de Lamballerie, C., Pizzorno, A., Dubois, J., Julien, T., Padey, B., Bouveret, M., Traversier, A., Legras-Lachuer, C., Lina, B., Boivin, G., Terrier, O., Rosa-Calatrava, M.. DOI 10.1038/s41598-019-48013-7
Antiviral agents in development for zika virus infections Pharmaceuticals, 2019. Baz, M., Boivin, G.. DOI 10.3390/ph12030101
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.